A few companies making headlines on Wednesday:
Amarain Corp (AMRN): Shares of Amarin (AMRN) jumped by well over a dollar during intra-day trading on Wednesday, on volume nearly four times the daily norm. No news was released in conjunction with the price increase and call options were also being bought up by the boat load.
Amarin has been battling patent concerns after the US Patent and Trademark Office (USPTO) rejected a patent for AMR-101, a treatment for high triglycerides that is before the FDA for approval review and is expected to receive a regulatory nod later this year.
Wednesday's action should have AMRN on the radar for the remainder of the week.
BioDelivery Sciences (BDSI): The news presses have been busy with updates regarding BioDelivery Sciences (BDSI) this week, most relating to ongoing patent litigation between BDSI and Monosol RX, LLC.
The US Patent and Trademark Office (USPTO) had ruled in favor of BioDelivery in relation to the patent dispute, and a federal court then decided to grant a stay of litigation until the USPTO issues its own final verdict.
Monosol, however, remains undeterred and has vowed to fight on.
BioDelivery also noted earlier in the week that the company would delay its re-launch of ONSOLIS for the treatment of breakthrough cancer pain while appearance concerns raised by the FDA were resolved. The setback comes after a long period of waiting for BDSI and partner Meda as the FDA approved a Risk Evaluation Mitigation Strategy (REMS) that covered all transmucosal fentanyl products, including ONSOLIS.
The news was mixed for BioDelivery this week, but the lawsuit resolution looks as if it may turn out in BioDelivery's favor, while the long term potential for ONSOLIS remains in tact - even if the relaunch is again delayed.
Human Genome Sciences (HGSI): Shares of Human Genome Sciences (HGSI) have also traded with volatility over the past couple of weeks, as rumors of a buyout from partner GlaxoSmithKline (GSK) continue to circulate the wires.
A late-week spike last week was nullified by heavy short interest, but shares popped for a short time on Wednesday, enough to make investors pay attention and wonder if Glaxo news is actually going to materialize.
Glaxo is already partnered with Human Genome for the commercialization of Benlysta, recently-approved for the treatment of lupus.
Agenus, Inc. (AGEN): Shares of Agenus (AGEN) spiked another 10% during intra-day trading on Wednesday, continuing a run that was ignited by the expanding of an agreement with GlaxoSmithKline (GSK) earlier this month that had the buyout rumors swirling.
In the agreement, geared around Agenus' vaccine adjuvant QS-21 Stimulon, Glaxo was granted a 'first right of refusal' for any buyout offers Agenus may receive in relation to the company as a whole or any of its pipeline products.
The protracted movement in share price has put this company on the map again.
Aside from a brief period last year when AGEN was brought into news circles regarding the success of GSK's late stage malaria vaccine - in which Stimulon is used and AGEN will receive modest royalties - this company has been relatively dormant since the European medical regulators denied approval of the experimental cancer immunotherapy treatment Prophage (formerly Oncophage) for the treatment of kidney cancer.
Oncophage had been approved in Russia for that indication, but nothing ever commercially materialized after the approval.
Prophage is currently being tested in a Phase II trial for the possible treatment of glioma, and the early signs of success have been encouraging.
Agenus is still a long way from recognizing any significant revenue, barring any partnership money coming in, but the expansion of the GSK deal is credible enough to have sparked the most recent price run.
It's always a good idea, in my opinion, to entertain the option of flipping a few trading shares into runs such as this one - especially in the highly volatile biotech sector - given the nature of the beast that has the higher prices disappear as quickly as they materialized (see: Oncothyreon (ONTY) as one example), but regardless of how long the price increase lasts, Agenus is back on the map.
AGEN made the Nasdaq's top gainers list on Wednesday, and investors will be watching on Thursday to see if the run continues.
Celsius Holdings (CELH): Celsius Holdings (CELH.PK) is a very lightly-traded stock, so when an eight percent gain materializes even on volume equal to the daily norm, it is almost worth noting. The company has showed signs of renewed price stability over the past few quarters, although sales of the Celsius calorie-burning pre-workout beverage (and powder packets) are still far from where company officials and investors thought they would be by now.
A secure niche for the Celsius products looks to be forming, and any momentum in sales could quickly attract new investors to the company.
CELH is one to keep on the radar again.
Advanced Cell Technology (ACTC.OB): Advanced Cell Technology (ACTC.OB) filed a direct proxy with the SEC this week containing a shareholder proposal to undertake a reverse stock split. The move is a logical next step for the company's development, as its technology could be a game-changer in the field of regenerative medicine.
Early results from a human trial testing Advanced Cell's retinal pigment epithelium (RPE) stem cell line have been encouraging and it could be time for this company to land a major partner.
Investors will be watching as this company takes the next step in its evolution into a big player in the healthcare sector.
Disclosure: Long ACTC, CELH, HGSI, BDSI, AGEN.
Contact VFC's Stock House: firstname.lastname@example.org
Originally published at: htpp://vfcsstockhouse.com